HARP Profile
Harpoon Therapeutics Inc (HARP) is a clinical-stage immunotherapy company that develops biologic drugs to treat cancer and other diseases. The company is based in South San Francisco, California, and was founded in 2015.
Harpoon Therapeutics is focused on developing its proprietary Tri-specific T cell Activating Construct (TriTAC) platform, which is designed to harness the power of the body's immune system to fight cancer. TriTAC molecules are engineered to bind to cancer cells and T cells, thereby activating the T cells to attack and kill the cancer cells.
The company's lead product candidate is HPN424, a TriTAC molecule targeting prostate-specific membrane antigen (PSMA) that is being evaluated in a Phase 1 clinical trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company is also developing HPN536, a TriTAC molecule targeting mesothelin, for the treatment of ovarian and pancreatic cancers.
In addition to its TriTAC platform, Harpoon is also developing a pipeline of T cell engager products for the treatment of hematologic malignancies, including HPN217, which targets multiple myeloma, and HPN328, which targets B-cell malignancies.
As of September 30, 2021, Harpoon had cash, cash equivalents, and short-term investments of $428.1 million, which the company believes will be sufficient to fund its operations through 2024.
|
